133804-44-1

Basic information

• Product Name: 5-METHYL-2-(1-PIPERAZINYL)BENZENESULFONIC ACID MONOHYDRATE
• Synonyms: 5-METHYL-2-(1-PIPERAZINYL)BENZENESULFONIC ACID MONOHYDRATE
• CAS NO: 133804-44-1
• Molecular Formula: C₁₁H₁₆N₂O₃S
• Molecular Weight: 274.34
• Mol File: 133804-44-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.302g/cm³
• Refractive Index: 1.582
• PKA: -1.76±0.42(Predicted)
• CAS DataBase Reference: 5-METHYL-2-(1-PIPERAZINYL)BENZENESULFONIC ACID MONOHYDRATE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-2-(1-PIPERAZINYL)BENZENESULFONIC ACID MONOHYDRATE(133804-44-1)
• EPA Substance Registry System: 5-METHYL-2-(1-PIPERAZINYL)BENZENESULFONIC ACID MONOHYDRATE(133804-44-1)

Safety Data

• Hazardous Substances Data: 133804-44-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H16N2O3S/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13/h2-3,8,12H,4-7H2,1H3,(H,14,15,16)

Upstream product

• 110-85-0 piperazine 
• 12775-96-1 copper 
• 192509-24-3 5-methyl-2-(1-piperazinyl)-benzenesulfonic acid monohydrate 

Relevant articles and documents

CRYSTALLINE POLYMORPHISM OF 5-METHYL-2-(PIPERAZIN-1-YL)BENZENESULFONIC ACID

The present invention provides novel crystals of 5-methyl-2-(piperazin-1-yl)benzenesulfonic anhydrate and monohydrate. The present invention provides type I crystal and type II crystal of 5-methyl-2-(piperazin-1-yl)benzenesulfonic anhydrate, which show pa

REMEDIES AND/OR PREVENTIVES FOR DIABETIC ISCHEMIC HEART DISEASES

An agent for therapeutic and /or prophylactic treatment of heart failure or arrhythmia in diabetic ischemic heart disease, which comprises as an active ingredient an aminobenzenesulfonic acid derivative represented by the following general formula (I): (wherein R1 represents, for example, hydrogen atom; R2 represents, for example, hydrogen atom; and n represents an integer of from 1 to 4) or a salt thereof, or a hydrate thereof or a solvate thereof, and an agent for therapeutic and /or prophylactic treatment of diabetic ischemic heart disease wherein said agent improves a cardiac dysfunction in diabetic ischemic heart disease.

Remedies and/or preventives for nervous system disorders

A therapeutic and/or prophylactic agent for nervous system disorder comprising as the active ingredient substances having an effect of improving calcium ion uptake of cardiac sarcoplasmic reticulum and/or an effect of inhibiting overaccumulation of intracellular calcium ions is offered. Preferably, the therapeutic and/or prophylactic agent for disease selected from the group consisting of cerebrovascular disease, traumatic head injury and postencephalitis and the therapeutic and/or prophylactic agent for disease selected from the group consisting of dementia and neuronal degeneration disease are offered.